| Mrs Ashley Hudson, CAA | |
|
504 Medical Center Blvd, Conroe, TX 77304-2808 | |
| (936) 539-1111 | |
| Not Available |
| Full Name | Mrs Ashley Hudson |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 4 Years |
| Location | 504 Medical Center Blvd, Conroe, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811522204 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hca Houston Healthcare Conroe | Conroe, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Independent Physicians Network Pllc | 5496029407 | 132 |
News Archive
Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.
The President's Emergency Plan for AIDS Relief, the ambitious U.S. government program begun in 2003, has cut the death toll from HIV/AIDS through 2007 by more than 10 percent in targeted countries in Africa, though it has had no appreciable effect on prevalence of the disease in those nations, according to a study from the Stanford University School of Medicine that is the first to evaluate these outcomes.
Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis.
Clinicians around the world have long suspected that bacteraemia due to Staphylococcus aureus has a worse outcome in women compared to men, but direct evidence has been elusive.
› Verified 6 days ago
| Entity Name | Independent Physicians Network Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396274676 PECOS PAC ID: 5496029407 Enrollment ID: O20170914001408 |
News Archive
Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.
The President's Emergency Plan for AIDS Relief, the ambitious U.S. government program begun in 2003, has cut the death toll from HIV/AIDS through 2007 by more than 10 percent in targeted countries in Africa, though it has had no appreciable effect on prevalence of the disease in those nations, according to a study from the Stanford University School of Medicine that is the first to evaluate these outcomes.
Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis.
Clinicians around the world have long suspected that bacteraemia due to Staphylococcus aureus has a worse outcome in women compared to men, but direct evidence has been elusive.
› Verified 6 days ago
| Entity Name | Texas Anesthesia Team Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467037937 PECOS PAC ID: 6608285424 Enrollment ID: O20210507001442 |
News Archive
Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.
The President's Emergency Plan for AIDS Relief, the ambitious U.S. government program begun in 2003, has cut the death toll from HIV/AIDS through 2007 by more than 10 percent in targeted countries in Africa, though it has had no appreciable effect on prevalence of the disease in those nations, according to a study from the Stanford University School of Medicine that is the first to evaluate these outcomes.
Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis.
Clinicians around the world have long suspected that bacteraemia due to Staphylococcus aureus has a worse outcome in women compared to men, but direct evidence has been elusive.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Ashley Hudson, CAA 124 Plantation Dr, Waller, TX 77484-9594 Ph: (832) 631-0250 | Mrs Ashley Hudson, CAA 504 Medical Center Blvd, Conroe, TX 77304-2808 Ph: (936) 539-1111 |
News Archive
Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.
The President's Emergency Plan for AIDS Relief, the ambitious U.S. government program begun in 2003, has cut the death toll from HIV/AIDS through 2007 by more than 10 percent in targeted countries in Africa, though it has had no appreciable effect on prevalence of the disease in those nations, according to a study from the Stanford University School of Medicine that is the first to evaluate these outcomes.
Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis.
Clinicians around the world have long suspected that bacteraemia due to Staphylococcus aureus has a worse outcome in women compared to men, but direct evidence has been elusive.
› Verified 6 days ago
Mehik Khawaja, CAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 936-539-1111 | |
Ms. Xiao Zhu, AA-C Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 936-539-1111 | |
Amelia Chen, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 936-539-1111 | |
Jeffrey Mansfield-walker, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 936-539-1111 | |
Christopher Lemus, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 936-539-1111 |